

AMENDMENTS

In the Specification:

Please amend the paragraph at page 24, line 29 through page 25, line 6 as follows:

For preparation of Mabs and Bi-MAbs, Wistar rats were immunized with 2×10^7 Hepa 1-6 cells in CFA. Following three additional boosts with the same cells in ICFA over an 8 week period, spleen cells from immunized rats were fused with YB2/0 rat myelomas as previously described (J. Alan & T. Robin, in: Immunochimistry in Practice, Chapter 2 (Blackwell, New York, 2d ed. 1988)). More than twenty Ig-producing hybridomas were selected by immunofluorescent staining. Three antibodies reacted with hepa 1-6 cells by flow cytometry analysis. These Mabs separately recognized a 55 Kd, 95 Kd, 115 Kd or 210 Kd glycoprotein expressed on most tumor cells as determined by immunoprecipitation. The Mabs were designated as anti-gp55 (produced by the hybridoma cell line having a deposit accession number CCTCC-C200305), anti-gp95 (produced by the hybridoma cell line having a deposit accession number CCTCC-C200306), anti-gp115 and anti-gp210 (produced by the hybridoma cell line having a deposit accession number CCTCC-C200307), respectively.